SLNSW-Umbralisib, a novel PI3Kδ and casein kinase-1ε in...-TN_cdi_proquest_journals_2019871584

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study

Full title: Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study

Author/creator: Burris, Howard A, Flinn, Ian W, Patel, Manish R, Fenske, Timothy S, Deng, Changchun, Brander, Danielle M, Gutierrez, Martin, Essell, James H, Kuhn, John G, Miskin, Hari P, Sportelli, Peter, Weiss, Michael S, Vakkalanka, Swaroop, Savona, Michael R, O'Connor, Owen A.

Call Numbers:

Record Identifier: TN_cdi_proquest_journals_2019871584

Language: English

Formats: Articles

Publishers: England: Elsevier Ltd

Permalink: https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2019871584

Articles

Articles

Export this record

Export selected records

  • Export to excel
  • Permalink

    • Export record to excel

    File type to download

    Beta version

    Record title

    Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study

    Record identifier

    TN_cdi_proquest_journals_2019871584

    Record permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2019871584

    Share

    Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study

    ACCESS
    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2019871584

    Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study

    Full title

    Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study

    Author / Creator

    Burris, Howard A ; Flinn, Ian W ; Patel, Manish R ; Fenske, Timothy S ; Deng, Changchun ; Brander, Danielle M ; Gutierrez, Martin ; Essell, James H ; Kuhn, John G ; Miskin, Hari P ; Sportelli, Peter ; Weiss, Michael S ; Vakkalanka, Swaroop ; Savona, Michael R ; O'Connor, Owen A

    Publisher

    England: Elsevier Ltd

    Journal title

    The lancet oncology, 2018, Vol.19 (4), p.486-496

    Record Identifier

    TN_cdi_proquest_journals_2019871584

    Language

    English

    Formats

    Articles

    Publication information

    Publisher

    Subjects

    Subjects and topics

    1-Phosphatidylinositol 3-kinase Cancer Cancer therapies Casein Chronic lymphocytic leukemia Colitis Cytochrome Cytokines Diarrhea Drug dosages Enzyme inhibitors Fatigue Kinases Leukemia Lymphocytes B Lymphocytes T Lymphoma Mutation Nausea Neutropenia Oncology Patients Pharmacokinetics Safety Studies Thrombocytopenia Toxicity

    More information

    — SCOPE AND CONTENTS

    Contents

    — ALTERNATIVE TITLES

    Full title

    — AUTHORS, ARTISTS AND CONTRIBUTORS

    Author / Creator

    Identifiers

    — PRIMARY IDENTIFIERS

    Record Identifier

    TN_cdi_proquest_journals_2019871584

    Permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2019871584

    — OTHER IDENTIFIERS

    ISSN

    E-ISSN

    DOI

    How to access this item

    Online

    1 item

    How to access?

    Login with a Library card

    Full text available >

    About resource >

    View in old catalogue

    Connecting people and collections